234. ペルオキシソーム病（副腎白質ジストロフィーを除く。） Peroxisomal disease (except Adrenoleukodystrophy) Clinical trials / Disease details

臨床試験数 : 39 /  薬物数 : 35 - (DrugBank : 12) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2015-003142-51-NL
(EUCTR)		21/07/201617/11/2015An Early Phase Study of DCR-PH1 in Patients with an Inherited Disorder Resulting in Overproduction of OxalateA Phase 1 Study of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1) Primary Hyperoxaluria Type 1
MedDRA version: 18.1;Level: PT;Classification code 10020703;Term: Hyperoxaluria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]		Product Name: DCR-PH1
INN or Proposed INN: Not Yet Assigned
Other descriptive name: DCR-1171X		Dicerna Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes		42Phase 1United States;France;Israel;Germany;Netherlands;United Kingdom
2EUCTR2015-003142-51-GB
(EUCTR)		11/04/201606/10/2015An Early Phase Study of DCR-PH1 in Patients with an Inherited Disorder Resulting in Overproduction of OxalateA Phase 1 Study of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1) Primary Hyperoxaluria Type 1
MedDRA version: 18.0;Level: PT;Classification code 10020703;Term: Hyperoxaluria;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]		Product Name: DCR-PH1
INN or Proposed INN: Not Yet Assigned
Other descriptive name: DCR-1171X		Dicerna Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes		42 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;United States;Israel;Netherlands;Germany;United Kingdom